This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBMG Cellular Biomedicine Group (CBMG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cellular Biomedicine Group Stock (NASDAQ:CBMG) 30 days 90 days 365 days Advanced Chart Get CBMG alerts:Sign Up Key Stats Today's Range N/A50-Day Range$17.67▼$19.7552-Week Range N/AVolume8,375 shsAverage Volume129,776 shsMarket Capitalization$384.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York. Read More Receive CBMG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellular Biomedicine Group and its competitors with MarketBeat's FREE daily newsletter. Email Address CBMG Stock News Headlines105 Oregon US Cellular workers to be laid off as company attempts to sell to T-MobileApril 12, 2025 | msn.comNearly 500 US Cellular workers to be laid off in eastern IowaApril 9, 2025 | msn.comOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.August 2 at 2:00 AM | InvestorPlace (Ad)Google sunsets Play Store carrier billing program, with US Cellular bowing outMarch 29, 2025 | msn.comUS Cellular wins tower battle in Town of Fond du Lac on a technicalityFebruary 12, 2025 | msn.comUS Cellular to Sell Certain Spectrum Licenses to AT&T For $1.02 BillionNovember 8, 2024 | msn.comUS Cellular agrees to sell $1 billion in assets to rival carrierNovember 8, 2024 | bizjournals.comIntra-Cellular bolsters Caplyta data with another Phase III winNovember 6, 2024 | finance.yahoo.comSee More Headlines CBMG Stock Analysis - Frequently Asked Questions How were Cellular Biomedicine Group's earnings last quarter? Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) announced its quarterly earnings data on Monday, November, 9th. The biotechnology company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.25. The biotechnology company had revenue of $0.03 million for the quarter. What other stocks do shareholders of Cellular Biomedicine Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellular Biomedicine Group investors own include CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), Aduro Biotech (ADRO), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Bristol Myers Squibb (BMY) and Intellia Therapeutics (NTLA). Company Calendar Last Earnings11/09/2020Today8/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CBMG CIK1378624 Webwww.cellbiomedgroup.com Phone347-905-5663FaxN/AEmployees217Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$49.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-144.80% Return on Assets-61.68% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.47 Sales & Book Value Annual Sales$340 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / BookN/AMiscellaneous Outstanding Shares19,478,000Free FloatN/AMarket Cap$384.69 million OptionableOptionable Beta1.35 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:CBMG) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellular Biomedicine Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellular Biomedicine Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.